Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Miragen Therapeutics Inc (MGEN)

Miragen Therapeutics Inc (MGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,928
  • Shares Outstanding, K 3,908
  • Annual Sales, $ 4,460 K
  • Annual Income, $ -41,870 K
  • 60-Month Beta 1.66
  • Price/Sales 47.83
  • Price/Cash Flow N/A
  • Price/Book 4.16
Trade MGEN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -10.65
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/10/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -2.61
  • Number of Estimates 4
  • High Estimate -1.27
  • Low Estimate -5.67
  • Prior Year -4.65
  • Growth Rate Est. (year over year) +43.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.02 +43.59%
on 12/29/20
25.67 -10.36%
on 01/14/21
+3.06 (+15.34%)
since 12/18/20
3-Month
7.08 +225.00%
on 10/22/20
25.67 -10.36%
on 01/14/21
+15.21 (+195.00%)
since 10/19/20
52-Week
4.66 +393.25%
on 03/19/20
34.05 -32.42%
on 01/30/20
+13.11 (+132.42%)
since 01/17/20

Most Recent Stories

More News
Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030

Reportlinker.com announces the release of the report "Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090627/?utm_source=GNW

DVAX : 19.23 (+2.34%)
IONS : 36.61 (+0.14%)
JAZZ : 134.52 (+3.84%)
MRK : 73.27 (+1.71%)
MGEN : 23.01 (-0.09%)
SRPT : 90.08 (+2.98%)
Global $1.25 Billion Oligonucleotide Therapy Markets, 2015-2019, 2023F, 2025F, 2030F

, /PRNewswire/ -- The report has been added to offering.

DVAX : 19.23 (+2.34%)
IONS : 36.61 (+0.14%)
JAZZ : 134.52 (+3.84%)
MRK : 73.27 (+1.71%)
MGEN : 23.01 (-0.09%)
NVS : 83.93 (+1.36%)
SRPT : 90.08 (+2.98%)
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

-- Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director

VRDN : 14.91 (+6.50%)
MGEN : 23.01 (-0.09%)
miRagen Enters into License Agreement with Xencor for use of Xtend(TM) Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor's Xtend(TM) half-life extension technology

MGEN : 23.01 (-0.09%)
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

-- Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance multiple compounds through Phase 2 proof of concept studies in TED and expand its orphan disease...

MGEN : 23.01 (-0.09%)
Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.

ARNA : 60.32 (-0.56%)
EBS : 53.60 (-0.46%)
RGEN : 321.81 (+2.78%)
MGEN : 23.01 (-0.09%)
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus

Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.

MRK : 73.27 (+1.71%)
EBS : 53.60 (-0.46%)
IOVA : 25.29 (+1.32%)
MGEN : 23.01 (-0.09%)
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q3 revenues increase year over year.

BLRX : 2.80 (+2.47%)
SRPT : 90.08 (+2.98%)
EBS : 53.60 (-0.46%)
MGEN : 23.01 (-0.09%)
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact

Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.

BMY : 61.06 (+1.51%)
EBS : 53.60 (-0.46%)
CLVS : 4.53 (+2.03%)
MGEN : 23.01 (-0.09%)
Perrigo (PRGO) Q3 Earnings Beat, Revenues Miss, Stock Up

Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales. Recovery in other two segments encouraging.

BLRX : 2.80 (+2.47%)
PRGO : 42.85 (+0.16%)
EBS : 53.60 (-0.46%)
MGEN : 23.01 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder,...

See More

Key Turning Points

3rd Resistance Point 24.55
2nd Resistance Point 24.22
1st Resistance Point 23.62
Last Price 23.01
1st Support Level 22.69
2nd Support Level 22.36
3rd Support Level 21.76

See More

52-Week High 34.05
Last Price 23.01
Fibonacci 61.8% 22.82
Fibonacci 50% 19.36
Fibonacci 38.2% 15.89
52-Week Low 4.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar